Page last updated: 2024-11-04

ioversol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ioversol is a non-ionic, iodinated contrast medium used in diagnostic imaging procedures. It is a triiodinated derivative of benzoic acid, and its synthesis involves a complex chemical reaction sequence. Ioversol is known for its high contrast enhancement properties, allowing for clearer visualization of anatomical structures in X-ray, CT, and MRI scans. Its effects include temporary changes in blood flow and mild allergic reactions in some individuals. Ioversol is studied extensively to improve its safety and efficacy, as well as to develop new contrast agents with enhanced properties. It is a vital tool in medical diagnosis, aiding in the detection and monitoring of various diseases and conditions.'

Cross-References

ID SourceID
PubMed CID3741
CHEMBL ID1200614
CHEBI ID31717
SCHEMBL ID24711
MeSH IDM0154765

Synonyms (92)

Synonym
AC-536
optiray
IOVERSOL ,
BSPBIO_000955
optiray 160
optiray 320
brn 7155654
ioversolum [latin]
optiray 350
n,n'-bis(2,3-dihydroxypropyl)-5-(n-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamide
mp-328
optiray 240
1,3-benzenedicarboxamide, n,n'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-
NCGC00016956-01
cas-87771-40-2
PRESTWICK3_000878
BPBIO1_001051
PRESTWICK2_000878
NCGC00179364-01
AB00513943
ioversol (jan/usp/inn)
87771-40-2
D01555
optiray (tn)
PRESTWICK0_000878
SPBIO_002876
PRESTWICK1_000878
CHEMBL1200614
mp 328
HMS1570P17
1-n,3-n-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
HMS2097P17
optiray 300
n3rib7x24k ,
ioversolum
ioversol [usan:usp:inn:ban]
unii-n3rib7x24k
nsc760064
8771-40-2
pharmakon1600-01503837
nsc-760064
dtxcid0025521
tox21_110709
dtxsid2045521 ,
FT-0627284
AKOS015896385
S5013
BRD-A65818372-001-01-2
ioversol [usan]
ioversol [usp-rs]
ioversol [who-dd]
ioversol [mart.]
ioversol [jan]
ioversol [mi]
ioversol [usp monograph]
ioversol [orange book]
ioversol [vandf]
ioversol [inn]
CCG-213209
SCHEMBL24711
tox21_110709_1
NCGC00179364-03
AMDBBAQNWSUWGN-UHFFFAOYSA-N
Q-201247
CS-7483
AB00513943_02
loversol
n,n'-bis (2,3-dihydroxypropyl)-5-[n-(2-hydroxyethyl) -glycolamido] -2,4,6-triiodoisophthalamide
DB09134
sr-01000872680
SR-01000872680-1
CHEBI:31717
HMS3714P17
HY-B1410
n1,n3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-n-(2-hydroxyethyl)acetamido)-2,4,6-triiodoisophthalamide
Q6064187
AS-12851
BCP11109
mp-328mp-328
n1,n3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-n-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
EN300-19767831
ioversol (usp monograph)
optiray320
ioversolo
ioversol (usan:usp:inn:ban)
optiray350
n,n'-bis (2,3-dihydroxypropyl)-5-(n-(2-hydroxyethyl) -glycolamido) -2,4,6-triiodoisophthalamide
v08ab07
ioversol (mart.)
ioversolum (latin)
ioversol (usp-rs)
optiray300

Research Excerpts

Overview

Ioversol is a nonionic, triiodinated, water-soluble contrast medium. It is used to enhance the visualization of blood vessels, tissues, or organs.

ExcerptReferenceRelevance
"Ioversol is a commonly used non-ionic radiological contrast media in medical imaging to enhance the visualization of blood vessels, tissues, or organs. "( Contrast Media Ioversol Interferes with Urinalysis.
Cai, X; Tan, Y, 2023
)
2.71
"Ioversol is a safe and effective nonionic contrast agent for contrast-enhanced body CT."( Computed body tomography with a new nonionic contrast agent. Comparison of ioversol with sodium/meglumine diatrizoate.
Heiken, JP; James, MA; Lee, JK; McClennan, BL, 1989
)
1.23
"Ioversol is a new nonionic, triiodinated, water-soluble contrast medium. "( A double-blind study comparing the safety, tolerability, and efficacy of ioversol 320 and iopamidol-300 in cerebral angiography.
Kuehn, J; Ringel, K, 1989
)
1.95

Effects

Ioversol has a formula similar to that of other nonionic agents. It has been used in a variety of clinical studies.

ExcerptReferenceRelevance
"• Ioversol has a good safety profile in adult and pediatric patients when IV administered. "( A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration.
Bedioune, I; Darmon-Kern, E; Dekkers, IA; van der Molen, AJ, 2022
)
1.65
"Ioversol has a formula similar to that of other nonionic agents, and has been used in a variety of clinical studies."( Clinical experience with ioversol for angiography.
Bettmann, MA, 1989
)
1.3
"• Ioversol has a good safety profile in adult and pediatric patients when IV administered. "( A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration.
Bedioune, I; Darmon-Kern, E; Dekkers, IA; van der Molen, AJ, 2022
)
1.65
"Ioversol has a formula similar to that of other nonionic agents, and has been used in a variety of clinical studies."( Clinical experience with ioversol for angiography.
Bettmann, MA, 1989
)
1.3

Actions

ExcerptReferenceRelevance
"Ioversol demonstrated lower incidence of adverse reactions and less heat sensation in left coronary arteriography than those with iopamidol."( [Usefulness of ioversol (MP-328) in angiocardiography--a multicenter comparative study with iopamidol].
Harada, J; Kimura, K; Kozuka, T; Kuribayashi, S; Matsuyama, S; Morimoto, S; Shigeta, A; Takamiya, M; Umemura, J; Yamada, T, 1990
)
1.35

Treatment

ExcerptReferenceRelevance
"Ioversol treatment induced a significant increase in [Ca(2+)](i) and intracellular ROS."( Selective inhibition of the reverse mode of Na(+)/Ca(2+) exchanger attenuates contrast-induced cell injury.
Ding, G; Jia, R; Yang, D, 2013
)
1.11

Toxicity

Ioversol is considered to be the efficacious and safe contrast medium for the cardiovascular angiography. Administration of ioversol for contrast-enhanced CT examinations is associated with a low incidence of AEs and is generally safe and well tolerated.

ExcerptReferenceRelevance
" The results of these studies demonstrate that ioversol is an effective, well tolerated and safe contrast agent for intravenous excretory urography."( Ioversol in intravenous excretory urography. Evaluation of radiographic quality, patient tolerance and safety in four clinical studies.
Jahn, H; Müller-Späth, R, 1992
)
1.98
" These results indicate that ioversol could be used as a safe contrast medium in intravascular administration."( Comparative study of the adverse effects of various radiographic contrast media, including ioversol, a new low-osmolarity medium. II. The complement system and endothelial cells.
Akagi, M; Kitazumi, K; Masaki, S; Mio, M; Tasaka, K, 1991
)
0.79
" Safety was assessed by monitoring vital signs (blood pressure, pulse and respiration), clinical laboratory studies and observation of adverse effects prior to and after injection of contrast medium."( A double blind clinical study comparing the safety, tolerance and efficacy of ioversol 240 and iohexol 240 (Omnipaque 240) in ascending venography.
Spinks, BC; Wilkins, RA, 1990
)
0.51
" The study results suggest that ioversol is considered to be the efficacious and safe contrast medium for the cardiovascular angiography."( [Preliminary study and clinical evaluation method of ioversol in angiocardiography--establishment of safety evaluation parameters and reliability of radiographic quality evaluation].
Harada, J; Himi, K; Ide, M; Kuribayashi, S; Matsuyama, S; Morimoto, S; Shigeta, A; Takemoto, A; Umemura, J; Yamada, T, 1990
)
0.81
" When the acute intravenous toxicity of 35% I, wt/vol, ioversol was compared with 35% I, wt/vol, iohexol and 37% I, wt/vol, iopamidol in mice, no significant differences in LD50 values or general toxicity were found."( Acute and subacute toxicity studies of ioversol in experimental animals.
Blair, M; Coveney, J; Ralston, WH; Robbins, MS, 1989
)
0.79
" There were no clinically significant drug-related changes in vital signs or laboratory tests among the patients, and no drug-related adverse effects were reported."( Efficacy, safety, and tolerability of ioversol in intra-arterial digital subtraction angiography.
Miller, FJ; Osborn, AG; Pollei, SR, 1989
)
0.55
" There was only one adverse reaction in the entire study."( A double-blind comparative study of the safety, tolerability, and efficacy of ioversol and iohexol in peripheral and visceral arteriography.
Cutcliff, WB; Schwarten, DE, 1989
)
0.51
" The results indicate that ioversol was well tolerated in all patients and showed fewer adverse effects than conventional ionic agents."( Ioversol clinical safety summary.
Aten, EM; Benamor, M; Buy-Gandal, T; Harashe, LT; James, MA; Lankin, DG; McElvany, KD; Weinandt, WJ, 1989
)
2.02
" Adverse reactions were sought, physical examinations were performed, and standard hematology and serum chemistry values were measured before and 1 day after injection; a 72-hour serum creatinine level was also measured."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
" Mild adverse reactions were experienced by 10% of patients; there were no significant differences in reaction rates among contrast agents."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.29
"Iopromide at a dose of approximately 300 mg I/kg is safe and effective as an excretory urographic agent and is comparable in performance with ioversol and iopamidol."( Efficacy and safety of iopromide for excretory urography.
Amis, ES; Goldman, S; Hedgcock, M; Khazan, R; Landman, J; Lang, E; Leder, R; Newhouse, JH, 1994
)
0.49
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"We sought to report adverse event (AE) rates attributed to contrast administration in a pediatric cardiac catheterization lab and identify characteristics related to higher doses."( Contrast administration in pediatric cardiac catheterization: dose and adverse events.
Bergersen, L; Gauvreau, K; Lock, JE; Marshall, AC; Senthilnathan, S, 2009
)
0.35
" Fistulography alone, or with angioplasty, utilizing a low volume of iodinated contrast and sodium bicarbonate solution for prophylaxis, appears to be safe in the CKD stages 4 and 5 population."( Safety of low volume iodinated contrast administration for arteriovenous fistula intervention in chronic kidney disease stage 4 or 5 utilizing a bicarbonate prophylaxis strategy.
Benson, S; Eisenhart, E; Himmelfarb, J; Lacombe, P; Parker, MG; Schimelman, B; Zimmerman, R,
)
0.13
"To review adverse outcomes following contrast administration in a cohort of patients with sickle cell disease."( Safety of iodinated intravenous contrast medium administration in sickle cell disease.
Adams, S; Andrel, J; Axelrod, D; Ballas, SK; Campbell, KL; Feldman, AM; Hud, LM, 2012
)
0.38
" Medical records were reviewed for evidence of worsening crisis and occurrence of adverse events within 48 hours of contrast administration."( Safety of iodinated intravenous contrast medium administration in sickle cell disease.
Adams, S; Andrel, J; Axelrod, D; Ballas, SK; Campbell, KL; Feldman, AM; Hud, LM, 2012
)
0.38
" Minor adverse events followed 16% of studies, with new or worsening pain being most common (12%)."( Safety of iodinated intravenous contrast medium administration in sickle cell disease.
Adams, S; Andrel, J; Axelrod, D; Ballas, SK; Campbell, KL; Feldman, AM; Hud, LM, 2012
)
0.38
"Administration of ioversol for contrast-enhanced CT examinations is associated with a low incidence of AEs and is generally safe and well tolerated."( An observational study to evaluate the efficiency and safety of ioversol pre-filled syringes compared with ioversol bottles in contrast-enhanced examinations.
Buerke, B; Vogl, TJ; Wessling, J, 2012
)
0.95
"The purpose of the study is to examine the incidence of adverse reactions caused by non-ionic contrast media in selected patients after desensitization treatment and to evaluate the safety profile of organ iodine contrast media (i."( Safety profile and protocol prevention of adverse reactions to uroangiographic contrast media in diagnostic imaging.
Brunese, L; D'Amora, M; D'Andrea, A; Di Grezia, G; Grassi, R; Mandato, Y; Reginelli, A; Rossi, C; Rotondi, A,
)
0.13
"This study aimed to investigate the image quality and adverse events (AEs) of ethiodized poppyseed oil (EPO) compared with ioversol as contrast agents in hysterosalpingography (HSG)."( Ethiodized poppyseed oil versus ioversol for image quality and adverse events in hysterosalpingography: a prospective cohort study.
Hong, F; Jiang, S; Lei, W; Tan, Y; Wang, F; Zeng, T; Zheng, S; Zhou, B, 2019
)
1
"This study was aimed at comparing the adverse drug reactions (ADRs) arising from the use of iodinated contrast medium (ICM) and gadolinium-based contrast media (GBCM), and to provide a basis for the clinical selection of contrast media."( Clinical safety evaluation of contrast agents based on real-world evidence.
Huang, D; Huang, Y; Jiang, C; Jiang, X; Li, J; Lin, J, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"The purpose of this study was to determine the optimum imaging parameters for 2D-TOF MR venography (MRV) of the pelvis and suprapopliteal deep venous system in combination with off-resonance magnetization transfer constant (MTC) and to evaluate the use of MRV in patients suspected of having chronic deep venous thrombosis (DVT) by comparing its accuracy with that of conventional venography (CV)."( Two-dimensional time-of-flight MR venography: assessment with detection of chronic deep venous thrombosis in combination with magnetization transfer contrast.
Kawamitsu, H; Sugimura, K; Yoshikawa, K; Yoshizako, T,
)
0.13
"9 (TR ms/TE ms) combined with an off-resonance MTC technique."( Two-dimensional time-of-flight MR venography: assessment with detection of chronic deep venous thrombosis in combination with magnetization transfer contrast.
Kawamitsu, H; Sugimura, K; Yoshikawa, K; Yoshizako, T,
)
0.13
" Patients were randomly assigned to 2 equal protocol groups: protocol A used a PSCF, and protocol B involved the use of a PSCF combined with EDCM."( Exponentially Decelerated Contrast Media Injection Rate Combined With a Novel Patient-Specific Contrast Formula Reduces Contrast Volume Administration and Radiation Dose During Computed Tomography Pulmonary Angiography.
El-Merhi, F; Mayat, A; Saade, C,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The results of this study demonstrate that intestinal mixing kinetics have a dramatic impact on the ability of pharmaceutical excipients to modulate the oral bioavailability of peptide drugs like sCT."( Regional differences in intestinal spreading and pH recovery and the impact on salmon calcitonin absorption in dogs.
Lee, YH; Perry, BA; Sinko, PJ; Stern, W; Sutyak, JP, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The heart rate difference was analyzed by the logistic linear regression model with variables that included gender, age, body height, body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP) and the dosage of propranolol."( Effects of propranolol on the left ventricular volume of normal subjects during CT coronary angiography.
Jaw, FS; Jeng, CM; Mo, YH; Peng, SF; Wang, YC,
)
0.13
" The difference of heart rate was negatively correlated with the dosage of propranolol."( Effects of propranolol on the left ventricular volume of normal subjects during CT coronary angiography.
Jaw, FS; Jeng, CM; Mo, YH; Peng, SF; Wang, YC,
)
0.13
"The difference of heart rate is significantly influenced by gender and the dosage of propranolol."( Effects of propranolol on the left ventricular volume of normal subjects during CT coronary angiography.
Jaw, FS; Jeng, CM; Mo, YH; Peng, SF; Wang, YC,
)
0.13
" Single energy was used for the nonenhanced phase scanning, which was used for the radiation dosage comparison with dual-energy CT scanning."( Mixed Imaging on Port-Venous Phase of Contrast-Enhanced Dual-Source Dual-Energy Computed Tomography: A Measurement Method Based on Couinaud Segments.
Dong, H; Fang, W; Feng, Q; Jiang, C; Ma, Z; Shen, L; Sun, S; Xia, L,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amidobenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency5.01190.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (58)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (413)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (6.30)18.7374
1990's110 (26.63)18.2507
2000's108 (26.15)29.6817
2010's147 (35.59)24.3611
2020's22 (5.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.21 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index76.66 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials89 (19.06%)5.53%
Reviews13 (2.78%)6.00%
Case Studies45 (9.64%)4.05%
Observational1 (0.21%)0.25%
Other319 (68.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]